Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inwardly rectifying potassium channel 4.1 (Kir4.1), encoded by the KCNJ10 gene, is a member of the inwardly rectifying potassium channel family. It is predominantly expressed in glial cells of the central nervous system (astrocytes and oligodendrocytes), the inner ear (stria vascularis), and the basolateral membrane of the kidney's distal convoluted tubules. In the brain, Kir4.1 plays a critical role in spatial potassium buffering, clearing excess extracellular potassium ions released during neuronal activity, and maintaining glutamate homeostasis. In the inner ear, it is essential for generating the endocochlear potential required for hearing, while in the kidney, it supports sodium and magnesium reabsorption. Loss-of-function mutations in KCNJ10 cause EAST (Epilepsy, Ataxia, Sensorineural deafness, and Tubulopathy) or SeSAME syndrome, highlighting its physiological importance. Conversely, dysregulation of Kir4.1 is implicated in major depressive disorder, chronic pain, Huntington's disease, and epilepsy. Pharmacologically, Kir4.1 is inhibited by several tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and selective serotonin reuptake inhibitors (e.g., fluoxetine), which may contribute to their therapeutic effects by modulating glial-neuronal communication and increasing brain-derived neurotrophic factor (BDNF) expression. Developing selective modulators of Kir4.1 represents a promising therapeutic strategy for neurological and psychiatric disorders, though targeting this channel carries significant safety risks, including seizures, hearing impairment, and renal electrolyte imbalances.
Inwardly rectifying potassium channel blocker
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inwardly rectifying potassium channel 4.1 (Kir4.1) (Kir4.1).